DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Invega (Paliperidone) - Published Studies

 
 



Invega Related Published Studies

Well-designed clinical trials related to Invega (Paliperidone)

Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder. [2015]

Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. [2015]

Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia. [2014]

Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens. [2014]

Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder. [2013]

An integrated approach for establishing dosing recommendations: paliperidone for the treatment of adolescent schizophrenia. [2013]

Bilastine: in allergic rhinitis and urticaria. [2012]

A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. [2012]

Oral paliperidone: a review of its use in the management of schizoaffective disorder. [2011.06.01]

Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. [2011.03]

Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study. [2011.01]

A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. [2011]

Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. [2010.10]

[Efficacy of paliperidone extended-release tablets in the improvement of social functions in schizophrenics: a randomized and controlled study]. [2010.08.03]

A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. [2010.07]

Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects. [2010.07]

Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia. [2010.06]

A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. [2010.05]

A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. [2010.05]

Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. [2010.05]

Modeling the effectiveness of paliperidone ER and olanzapine in schizophrenia: meta-analysis of 3 randomized, controlled clinical trials. [2010.03]

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. [2010.02]

Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms. [2010.01]

Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects. [2010]

A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. [2010]

Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets. [2010]

Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia. [2010]

Intramuscular paliperidone palmitate. [2010]

Modeling the effectiveness of paliperidone ER and olanzapine in schizophrenia: meta-analysis of 3 randomized, controlled clinical trials. [2010]

A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. [2010]

Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms. [2010]

A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. [2010]

A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. [2010]

Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. [2010]

Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. [2010]

No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects. [2009.10]

Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. [2009.08.31]

Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms. [2009.08]

The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. [2009.07]

Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. [2009.06]

Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. [2008.07]

Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. [2008.01]

Efficacy and Safety of Paliperidone Extended-Release Tablets: Results of a 6-Week, Randomized, Placebo-Controlled Study. [2007.12.15]

Paliperidone: a new extended-release oral atypical antipsychotic. [2007.10]

Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. [2007.07]

Efficacy and Safety of Paliperidone Extended-Release Tablets: Results of a 6-Week, Randomized, Placebo-Controlled Study. [2007.06.27]

Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. [2007.02]

Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. [2007.02]

Well-designed clinical trials possibly related to Invega (Paliperidone)

Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS). [2013]

Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. [2012]

Change in employment status over 52 weeks in patients with schizophrenia: an observational study. [2011]

Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial. [2010.12]

Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers. [2010.11]

Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. [2010.11]

Relative bioavailability and pharmacokinetic comparison of two 2-mg risperidone tablet formulations: A single dose, randomized-sequence, double-blind, 2-way crossover study in healthy male volunteers in Thailand. [2010.09]

Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial. [2010]

Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder. [2010]

The risk of death among adult participants in trials of antipsychotic drugs in schizophrenia. [2010]

Bioequivalence evaluation of two strengths of risperidone tablet formulations in healthy volunteers. [2009.02]

One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia. [2008.12]

Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone. [2008.01]

Lack of bioequivalence between generic risperidone oral solution and originator risperidone tablets. [2007.05]

Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes. [2006.06]

Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. [2005.07]

Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. [2003.06]

Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together. [2002.12]

Risperidone: effects of formulations on oral bioavailability. [1997.05]

Other research related to Invega (Paliperidone)

Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia. [2014]

Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia. [2014]

Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. [2012]

Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability. [2012]

Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia. [2012]

Combination of citalopram plus paliperidone is better than citalopram alone in the treatment of somatoform disorder: results of a 6-week randomized study. [2012]

Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801. [2011.08.18]

Paliperidone overdose with delayed onset of toxicity. [2011.07]

Prolongation of cardiac ventricular repolarization under paliperidone: how and how much? [2011.06]

Paliperidone extended-release: does it have a place in antipsychotic therapy? [2011.03.11]

Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis. [2011.02.07]

Cardiac safety of the electroconvulsive therapy-paliperidone combination: a preliminary study. [2011.01]

Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study. [2011]

Tolerability of paliperidone: a meta-analysis of randomized, controlled trials. [2010.11]

Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania. [2010.10]

Serum concentrations of paliperidone versus risperidone and clinical effects. [2010.08]

Paliperidone extended release: a review of its use in the management of schizophrenia. [2010.07.09]

Hyperprolactinaemia during treatment with paliperidone. [2010.06]

Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews. [2010.05]

Paliperidone use in the elderly. [2010.04]

Intramuscular paliperidone palmitate. [2010.03.01]

A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats. [2010.03]

Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets. [2010.02]

Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia. [2010.02]

Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. [2010.02]

[Non-fatal paliperidone overdose: a case report]. [2010.01]

Exploratory analysis of psychiatric-related utilization and costs associated with paliperidone ER compared with other oral atypical antipsychotics using pharmacy claims from an administrative database. [2010]

[Efficacy of paliperidone extended-release tablets in the improvement of social functions in schizophrenics: a randomized and controlled study]. [Article in Chinese] [2010]

Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania. [2010]

Tolerability of paliperidone: a meta-analysis of randomized, controlled trials. [2010]

A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. [2010]

Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia. [2010]

Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. [2010]

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. [2010]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017